

Mayumi Nakagawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2575371/publications.pdf>

Version: 2024-02-01

49
papers

1,327
citations

471371

17
h-index

360920

35
g-index

52
all docs

52
docs citations

52
times ranked

1395
citing authors

#	ARTICLE	IF	CITATIONS
1	An Online Survey and Focus Groups for Promoting Cancer Prevention Measures. <i>Journal of Cancer Education</i> , 2022, 37, 1782-1789.	0.6	2
2	Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota. <i>PLoS ONE</i> , 2021, 16, e0237556.	1.1	4
3	Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. <i>Frontiers in Immunology</i> , 2021, 12, 645299.	2.2	9
4	Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures. <i>Cancer Control</i> , 2021, 28, 107327482110379.	0.7	1
5	Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review. <i>Preventive Medicine</i> , 2020, 141, 106242.	1.6	20
6	The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 8-16.	3.4	47
7	An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients. <i>Journal of Microbiological Methods</i> , 2019, 166, 105739.	0.7	13
8	Natural history of human papillomavirus and vaccinations in men: A literature review. <i>Health Science Reports</i> , 2019, 2, e118.	0.6	26
9	Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541989306.	0.8	9
10	Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with <i>Candida</i> skin test reagent as an adjuvant in C57BL/6 mice. <i>International Immunopharmacology</i> , 2018, 56, 249-260.	1.7	9
11	A novel prostate cancer immunotherapy using prostate-specific antigen peptides and <i>Candida</i> skin test reagent as an adjuvant. <i>SAGE Open Medicine</i> , 2018, 6, 205031211880020.	0.7	2
12	Japanesplex : A forensic SNP assay for identification of Japanese people using Japanese-specific alleles. <i>Legal Medicine</i> , 2018, 33, 17-22.	0.6	14
13	Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3099-3099.	0.8	3
14	Regulatory T Cells in Gynecologic Cancer. <i>MOJ Immunology</i> , 2018, 6, 34-42.	11.0	12
15	Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 563-573.	2.0	51
16	Genotyping of the c.1423C>T (p.P475S) polymorphism in the ADAMTS13 gene by APLP and HRM assays: Northeastern Asian origin of the mutant. <i>Legal Medicine</i> , 2016, 21, 1-4.	0.6	2
17	A novel prostate cancer immunotherapy using prostate specific antigen peptides and <i>Candida</i> skin test reagent as an immunostimulant.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14582-e14582.	0.8	0
18	A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine. <i>Clinical Trials</i> , 2015, 12, 199-204.	0.7	11

#	ARTICLE	IF	CITATIONS
19	A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with <i>Candida</i> skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. <i>Oncolmunology</i> , 2015, 4, e1031439.	2.1	39
20	Cross-Reactivity, Epitope Spreading, and <i>De Novo</i> Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. <i>Vaccine Journal</i> , 2015, 22, 679-687.	3.2	28
21	Early Defensive Mechanisms against Human Papillomavirus Infection. <i>Vaccine Journal</i> , 2015, 22, 850-857.	3.2	39
22	A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with <i>candida</i> skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3032-3032.	0.8	0
23	Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma. <i>Bone Marrow Research</i> , 2014, 2014, 1-7.	1.7	14
24	IL-12 secretion by Langerhans cells stimulated with <i>Candida</i> skin test reagent is mediated by dectin-1 in some healthy individuals. <i>Cytokine</i> , 2014, 65, 202-209.	1.4	17
25	A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot. <i>MOJ Immunology</i> , 2014, 1, .	11.0	7
26	<i>Candida</i> skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. <i>Vaccine</i> , 2013, 31, 5806-5813.	1.7	23
27	Role of Innate Immunity in Immune Enhancing Effects of <i>Candida</i> Skin Test Reagent. <i>FASEB Journal</i> , 2013, 27, 647.3.	0.2	0
28	Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. <i>The Journal of the Arkansas Medical Society</i> , 2013, 109, 160-3.	0.1	9
29	CD8 T-Cell Responses in Incident and Prevalent Human Papillomavirus Types 16 and 18 Infections. <i>ISRN Obstetrics & Gynecology</i> , 2012, 2012, 1-4.	1.2	4
30	Use of Interferon- γ ; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus. <i>Journal of Visualized Experiments</i> , 2012, , .	0.2	7
31	CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 63-70.	2.0	42
32	Chemotherapy Does Not Enhance CD34+ Cell Collection When Added to Growth Factor and Plerixafor in Patients Who Are Poor Mobilizers. <i>Blood</i> , 2011, 118, 4388-4388.	0.6	1
33	A Favorable Clinical Trend Is Associated With CD8 T-Cell Immune Responses to the Human Papillomavirus Type 16 E6 Antigens in Women Being Studied for Abnormal Pap Smear Results. <i>Journal of Lower Genital Tract Disease</i> , 2010, 14, 124-129.	0.9	27
34	Phase 1 Clinical Trial of Intralesional Injection of <i>Candida</i> Antigen for the Treatment of Warts. <i>Archives of Dermatology</i> , 2010, 146, 1431.	1.7	55
35	A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 301-308.	2.0	18
36	Cell-Mediated Immune Responses to Human Papillomavirus 16 E6 and E7 Antigens as Measured by Interferon Gamma Enzyme-Linked Immunospot in Women With Cleared or Persistent Human Papillomavirus Infection. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 508-512.	1.2	58

#	ARTICLE	IF	CITATIONS
37	A 15 Hour Dosing-Collection Interval for Plerixafor Is at Least as Effective as the Standard 10 Hour Interval.. <i>Blood</i> , 2009, 114, 2152-2152.	0.6	2
38	Molecular basis of complement factor I (CFI) polymorphism: one of two polymorphic suballeles responsible for CFI A is Japanese-specific. <i>Journal of Human Genetics</i> , 2008, 53, 1016-1021.	1.1	11
39	Memory T Cells Specific for Novel Human Papillomavirus Type 16 (HPV16) E6 Epitopes in Women Whose HPV16 Infection Has Become Undetectable. <i>Vaccine Journal</i> , 2008, 15, 937-945.	3.2	21
40	HLA Class I Binding Promiscuity of the CD8 T-Cell Epitopes of Human Papillomavirus Type 16 E6 Protein. <i>Journal of Virology</i> , 2007, 81, 1412-1423.	1.5	40
41	Detection of Human Papillomavirus Type 16-Specific T Lymphocytes by a Recombinant Vaccinia Virus-Based Enzyme-Linked Immunospot Assay. <i>Vaccine Journal</i> , 2007, 14, 362-368.	3.2	3
42	Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. <i>Cancer Immunity</i> , 2006, 6, 9.	3.2	9
43	Patterns of CD8 T-Cell Epitopes within the Human Papillomavirus Type 16 (HPV 16) E6 Protein among Young Women Whose HPV 16 Infection Has Become Undetectable. <i>Vaccine Journal</i> , 2005, 12, 1003-1005.	3.2	20
44	Different Methods of Identifying New Antigenic Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins. <i>Vaccine Journal</i> , 2004, 11, 889-896.	2.6	31
45	Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. <i>Transfusion</i> , 2004, 44, 1689-1694.	0.8	69
46	Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women. <i>Vaccine Journal</i> , 2002, 9, 877-882.	3.2	10
47	Cell-Mediated Immune Response to Human Papillomavirus Infection. <i>Vaccine Journal</i> , 2001, 8, 209-220.	2.6	200
48	Persistence of Human Papillomavirus Type 16 Infection Is Associated with Lack of Cytotoxic T Lymphocyte Response to the E6 Antigens. <i>Journal of Infectious Diseases</i> , 2000, 182, 595-598.	1.9	146
49	Cytotoxic T Lymphocyte Responses to E6 and E7 Proteins of Human Papillomavirus Type 16: Relationship to Cervical Intraepithelial Neoplasia. <i>Journal of Infectious Diseases</i> , 1997, 175, 927-931.	1.9	141